Xamoterolβ1-adrenoceptor部分激动剂:对心力衰竭的临床疗效。

文章的细节

引用

复制到剪贴板

马洛高频

Xamoterolβ1-adrenoceptor部分激动剂:对心力衰竭的临床疗效。

Br中国新药杂志。1989;28增刊1:23S-30S。

PubMed ID

2572251 (在PubMed

]

文摘

1。Xamoterol(科文,Carwin Corwil Xamtol, ICI 118587),β1-adrenoceptor部分激动剂,改善心力衰竭患者收缩压和舒张功能。2。双盲、随机研究与安慰剂比较xamoterol表明xamoterol的有益的血液动力学的影响产生显著改善运动能力和轻度至中度心衰患者症状。这些研究形成一个欧洲大型多中心研究项目的基础招募了超过1000名患者,随机,xamoterol(200毫克每日两次,n = 617),地高辛(0.125毫克,每日两次,n = 135)或安慰剂(n = 300) 3个月。3所示。通过测量运动能力和症状疗效评估。xamoterol组运动能力提高了37%,安慰剂组18%的改善。不同的症状评分衡量视觉模拟尺度和李克特xamoterol分数表示显著改善的红衣主教心力衰竭的症状,呼吸困难和疲劳。4所示。 Analyses of data from subsets of patients in the study showed that elderly patients, patients on no other heart failure therapy and patients with cardiomegaly all had similar improvements in exercise and symptoms to those seen in the whole study population. In the subset which included digoxin treatment, xamoterol produced significantly greater improvements in exercise capacity than digoxin (33% vs 17%, P less than 0.05) and was associated with fewer side-effects. 5. Xamoterol is therefore a promising addition to heart failure therapies currently available.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Xamoterol